{"id":"d1ec36c8-c7c0-51f1-bf8d-917f7b55c152","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:microbial-growth","predicate":"decreases_in_recorded_experiment","statement":"Allicin inhibited growth of tested bacterial isolates with substantial strain and assay variation.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"8688ddf5-1230-5af8-9a61-b583f57b2207","mechanism_event_label":"Allicin inhibited growth of tested bacterial isolates with substantial strain and assay variation.","subject":{"id":"85c86fcf-3060-5fae-b567-4f089990ab2d","slug":"allicin","display_name":"Allicin","entity_type_key":"small_molecule"},"object":{"id":"a53d9b35-c446-53ad-bc77-89cde12778ef","slug":"bacterial-allicin-growth-panel","display_name":"Growth of the tested bacterial isolates exposed to allicin","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8688ddf5-1230-5af8-9a61-b583f57b2207","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:microbial-growth-event","event_type":"experimental_observation","label":"Allicin inhibited growth of tested bacterial isolates with substantial strain and assay variation.","description":"**Laboratory antimicrobial activity.** Purified allicin inhibited multiple tested respiratory bacterial isolates, including some resistant to clinical antibiotics; susceptibility varied by organism and assay. The same investigation measured mammalian-cell and rat-lung-slice toxicity. Added glutathione reduced toxicity in those models. The experimental 1-mM glutathione condition must not be presented as a validated normal plasma concentration or a safe inhalation regimen. Luminal or surface accessibility is a hypothesis about delivery, not a calculation proving efficacy from nominal dose divided by fluid volume. [Reiter 2017](https://pmc.ncbi.nlm.nih.gov/articles/PMC6151386/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"85c86fcf-3060-5fae-b567-4f089990ab2d","slug":"allicin","display_name":"Allicin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Allicin exposure","sequence_order":0,"notes":""},{"entity":{"id":"a53d9b35-c446-53ad-bc77-89cde12778ef","slug":"bacterial-allicin-growth-panel","display_name":"Growth of the tested bacterial isolates exposed to allicin","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text available; selected claim-relevant methods, results, tables/figures and limitations reviewed. Supplemental proteome and all secondary findings are not exhaustively extracted.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Allicin exposure\", \"comparator\": \"Matched bacterial assay control\", \"endpoint\": \"Allicin inhibited growth of tested bacterial isolates with substantial strain and assay variation.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"In vitro clinical-isolate panel; liquid/vapor observations; primary full-text results.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not an organism-independent MIC, clinical infection therapy, or safe inhaled exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Allicin inhibited growth of tested bacterial isolates with substantial strain and assay variation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Diallylthiosulfinate (Allicin), a Volatile Antimicrobial from Garlic (Allium sativum), Kills Human Lung Pathogenic Bacteria, Including MDR Strains, as a Vapor. | 2017 | DOI 10.3390/molecules22101711 | PMID 29023413 | https://pubmed.ncbi.nlm.nih.gov/29023413/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6151386/ | https://doi.org/10.3390/molecules22101711","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 65-65; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"20314b11-3170-5238-97f7-ec06e19612ac","evidence_kind":"source_excerpt","locator":"Lines 65-65","start_line":65,"end_line":65,"excerpt":"**Laboratory antimicrobial activity.** Purified allicin inhibited multiple tested respiratory bacterial isolates, including some resistant to clinical antibiotics; susceptibility varied by organism and assay. The same investigation measured mammalian-cell and rat-lung-slice toxicity. Added glutathione reduced toxicity in those models. The experimental 1-mM glutathione condition must not be presented as a validated normal plasma concentration or a safe inhalation regimen. Luminal or surface accessibility is a hypothesis about delivery, not a calculation proving efficacy from nominal dose divided by fluid volume. [Reiter 2017](https://pmc.ncbi.nlm.nih.gov/articles/PMC6151386/)","model_system":"In vitro clinical-isolate panel; liquid/vapor observations; primary full-text results.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"10820a6b-594a-547d-97f9-906ab4cc1d6e","stable_key":"import-c836a883-ac18-5eb2-9971-2f0b542feba8","title":"Allicin: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"2475d3eb681100a0a34577a47b7cba5b251df866fbd6ce795122ccabee360018","revision_id":"590df96d-2ed1-5763-b04c-bf0e096e603c","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}